Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 267

Results For "NITI"

3216 News Found

Omicron sublineage BA.2 a Variant of Concern: WHO
News | February 23, 2022

Omicron sublineage BA.2 a Variant of Concern: WHO

As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern


Hovione and Zerion Pharma partner to market Dispersome technology platform
Biotech | February 23, 2022

Hovione and Zerion Pharma partner to market Dispersome technology platform

Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying


Taro to Acquire Alchemee from Galderma
Biotech | February 23, 2022

Taro to Acquire Alchemee from Galderma

Alchemee's flagship brand Proactiv@ is an iconic product synonymous with acne care


GSK introduces Haleon to the world
News | February 23, 2022

GSK introduces Haleon to the world

Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum


Bajaj Healthcare launches Magnesium L-Threonate in nutraceutical segment.
News | February 23, 2022

Bajaj Healthcare launches Magnesium L-Threonate in nutraceutical segment.

It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease among others


Dr Fabrice Egros gets an additional role at Lupin
People | February 23, 2022

Dr Fabrice Egros gets an additional role at Lupin

He will continue to lead business in LATAM and Asia regions in this new role


Complement Therapeutics raises €5 million seed financing
News | February 23, 2022

Complement Therapeutics raises €5 million seed financing

Appoints Dr Rafiq Hasan as CEO


Biorchestra announces US$45 million series C fundraising
News | February 23, 2022

Biorchestra announces US$45 million series C fundraising

he financing was significantly oversubscribed with high demand from both existing and new investors.


Vicore advances on new chemical entity from VP03 program
News | February 23, 2022

Vicore advances on new chemical entity from VP03 program

Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022


World’s first clinical trial for 3D bioprinted stem cell vascular grafts in China
Biotech | February 22, 2022

World’s first clinical trial for 3D bioprinted stem cell vascular grafts in China

Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.